A Survey of Payer Perspectives on Cannabis Use Disorder.
CONCLUSIONS: Based on these findings, payers see an unmet need for CUD treatment. Furthermore, FDA-approved pharmacotherapies for CUD will likely be reviewed quickly by payers, especially if data are provided on the likelihood of achieving abstinence and reduced resource utilization.
PMID: 29927691 [PubMed - as supplied by publisher]
Source: Substance Use and Misuse - Category: Addiction Tags: Subst Use Misuse Source Type: research
More News: Addiction | Clinical Trials | International Medicine & Public Health | Legislation | Managed Care | USA Health